Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
Company: Pfizer Inc.
Headquarters: New York, USA
Here are the drug patents we want Pfizer to put in the pool and why patients need them
Maraviroc (MVC)
Brand name: Selzentry
Maraviroc is one of a very new class of antiretrovirals that works in a totally new way to fight the HIV virus. This drug is used in the US and Europe by patients who have hit the end of the road with other available treatments. It could transform the prospects of some patients in developing countries who have also run out of treatment options. But Pfizer has indicated it won’t offer reduced prices for patients in developing countries. That’s why it’s very important to get the patents of this drug in the pool.
People Living with HIV/AIDS: India must not sacrifice us in trade agreement with Europe
Indian Court Gives Boost to Access to Medicines As Latest Appeal By Bayer is Rejected
UNITAID Patent Pool: Innovative Initiative Designed to Boost Access to Medicines is Adopted
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
